Drugs / BAY1101042
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03252002 | Aug 2017 → Apr 2019 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03235076 | Aug 2017 → Nov 2018 | impaired renal function disease | Bayer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY 1101042 | “Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days” NCT03252002 ↗3“Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)” NCT03235076 ↗ |
| Route | Oral | “Single oral dose of 10 mg BAY 1101042” NCT03235076 ↗ |